About: Vaccines against Coronaviruses: The State of the Art

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccines against Coronaviruses: The State of the Art Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccines against Coronaviruses: The State of the Art
Creator	Esposito, Susanna Argentiero, Alberto Affanni, Paola Conte, Cristiano Sogni, Francesco Veronesi, Licia
Source	Medline; PMC
abstract	The emerging epidemic caused by the new coronavirus SARS-CoV-2 represents the most important socio-health threat of the 21st century. The high contagiousness of the virus, the strong impact on the health system of the various countries and the absence to date of treatments able to improve the prognosis of the disease make the introduction of a vaccine indispensable, even though there are currently no approved human coronavirus vaccines. The aim of the study is to carry out a review of the medical literature concerning vaccine candidates for the main coronaviruses responsible for human epidemics, including recent advances in the development of a vaccine against COVID-19. This extensive review carried out on the vaccine candidates of the main epidemic coronaviruses of the past has shown that the studies in animal models suggest a high efficacy of potential vaccines in providing protection against viral challenges. Similar human studies have not yet been carried out, as the main trials are aimed at assessing mainly vaccine safety and immunogenicity. Whereas the severe acute respiratory syndrome (SARS-CoV) epidemic ended almost two decades ago and the Middle East respiratory syndrome (MERS-CoV) epidemic is now better controlled, as it is less contagious due to the high lethality of the virus, the current SARS-CoV-2 pandemic represents a problem that is certainly more compelling, which pushes us to accelerate the studies not only for the production of vaccines but also for innovative pharmacological treatments. SARS-CoV-2 vaccines might come too late to affect the first wave of this pandemic, but they might be useful if additional subsequent waves occur or in a post-pandemic perspective in which the virus continues to circulate as a seasonal virus.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.3390/vaccines8020309
bibo:pmid	32560340
has license	cc-by
sha1sum (hex)	da649ab7d4f9ceab6b367894488bfe0a114ce209
schema:url	https://doi.org/10.3390/vaccines8020309
resource representing a document's title	Vaccines against Coronaviruses: The State of the Art
has PubMed Central identifier	PMC7350246
has PubMed identifier	32560340
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:da649ab7d4f9ceab6b367894488bfe0a114ce209#body_text
is schema:about of	named entity 'EFFICACY' named entity 'POTENTIAL' named entity 'REVIEW OF' named entity 'TREATMENTS' named entity 'ABLE TO' named entity 'APPROVED' covid:arg/da649ab7d4f9ceab6b367894488bfe0a114ce209 named entity 'vaccines' named entity 'SARS-CoV-2 pandemic' named entity 'SARS-CoV-2' named entity 'epidemics' named entity '21st century' named entity 'vaccine' named entity 'animal models' named entity 'prognosis' named entity 'MERS-CoV' named entity 'live-attenuated' named entity 'neutralizing antibodies' named entity 'serum' named entity 'CpG' named entity 'glycoproteins' named entity 'vaccine' named entity 'HCoV-229E' named entity 'plasmid' named entity 'upper respiratory tract' named entity 'inactivated vaccine' named entity 'epidemic' named entity 'vaccine' named entity 'infection' named entity 'coronavirus vaccine' named entity 'live-attenuated vaccine' named entity 'recombinant vaccines' named entity 'gene sequences' named entity 'virus' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'live-attenuated' named entity 'protein' named entity 'vaccine' named entity 'vaccine' named entity 'virus' named entity 'vaccine' named entity 'immunogenic' named entity 'immunization' named entity 'genetic diversity' named entity 'MERS-CoV' named entity 'Viral antigens' named entity 'epitopes' named entity 'vaccine' named entity 'vaccine' named entity 'MERS-CoV' named entity 'vaccine against COVID-19' named entity 'MF59' named entity 'IFN' named entity 'receptor' named entity 'adverse reactions' named entity 'adjuvants' named entity 'virus' named entity 'epidemic' named entity 'mRNA' named entity 'TLR3' named entity 'neutralizing antibodies' named entity 'gene' named entity 'preclinical' named entity 'MERS-CoV' named entity 'seroconversion' named entity 'immunogenicity' named entity 'SARS-CoV-2' named entity 'viral infection' named entity 'host cells' named entity 'MERS-CoV' named entity 'recombinant vaccines' named entity 'epidemic' named entity 'SARS-CoV-2' named entity 'antibody titer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software